{"id":501299,"date":"2020-08-10T14:08:01","date_gmt":"2020-08-10T14:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=501299"},"modified":"2020-08-10T14:08:01","modified_gmt":"2020-08-10T14:08:01","slug":"hidradenitis-suppurativa-market-size-share-trends-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hidradenitis-suppurativa-market-size-share-trends-epidemiology-forecast-till-2030_501299.html","title":{"rendered":"Hidradenitis Suppurativa Market, Size, Share, Trends, Epidemiology Forecast till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hidradenitis Suppurativa Market, Size, Share, Trends, Epidemiology Forecast till 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Hidradenitis Suppurativa Market, Size, Share, Trends, Epidemiology Forecast till 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Hidradenitis Suppurativa Market Insights, Epidemiology and Market Forecast-2030\u2019 report delivers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">Hidradenitis Suppurativa (HS) is a chronic illness characterized by swollen, painful lesions, occurring in the armpit (axillae), groin, anal, and breast regions. This disease occurs due to blockage of hair follicles and secondary infection and sometimes inflammation of certain sweat glands (apocrine glands).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hidradenitis Suppurativa Epidemiology<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The total prevalent population of Hidradenitis Suppurativa in 7MM in 2017 was 6,053,923<\/li>\n<li>The US accounts for the highest prevalent population of Hidradenitis Suppurativa in 2017 was 2,766,042<\/li>\n<li>Around 40% of the Hidradenitis Suppurativa patients are presented with moderate to severe symptoms at diagnosis<\/li>\n<li>Hidradenitis Suppurativa is thrice more prevalent in females compared to males<\/li>\n<li>The disease occurs mostly in the age groups 18\u250059 years.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hidradenitis Suppurativa Market&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>The&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hidradenitis-suppurativa-market\">therapeutic market of Hidradenitis Suppurativa<\/a>&nbsp;in the 7MM in 2017 was USD 797.6 million<\/strong><\/li>\n<li>The&nbsp;market size of Hidradenitis Suppurativa&nbsp;in the US in 2017 was USD 426.2 million<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hidradenitis-suppurativa-market\">Hidradenitis Suppurativa&nbsp;<\/a>Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Growing Patient Pool<\/li>\n<li>Increasing awareness of the disease<\/li>\n<li>Improvement in healthcare economy and affordable treatment options<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hidradenitis Suppurativa Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Diagnostic barriers<\/li>\n<li>Treatment cost and a growing trend of complementary and alternative medicine<\/li>\n<li>Adverse events associated with biologics<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Hidradenitis Suppurativa, explaining its causes, signs and symptoms, pathophysiology and currently available therapies<\/li>\n<li>Comprehensive insight has been provided into the Hidradenitis Suppurativa epidemiology and treatment in the 7MM<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Hidradenitis Suppurativa are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<\/li>\n<li>A detailed review of Hidradenitis Suppurativa market; historical and forecasted is included in the report, covering drug outreach in the 7MM<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hidradenitis Suppurativa market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hidradenitis Suppurativa Emerging Therapies<\/strong><\/p>\n<p style=\"text-align: justify;\">(Drug: companies logos)<\/p>\n<ul style=\"text-align: justify;\">\n<li>IFX-1: InflaRx<\/li>\n<li>Cosentyx: Novartis Pharmaceuticals<\/li>\n<li>Avacopan: ChemoCentryx<\/li>\n<li>Bermekimab (MABp1): xbiotech\/ Janssen<\/li>\n<li>Bimekizumab: UCB Biopharma<\/li>\n<li>INCB054707: Incyte Corporation<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hidradenitis Suppurativa Marketed Drugs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Humira: AbbVie<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hidradenitis-suppurativa-market\"><span>Request for sample pages<\/span><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hidradenitis-suppurativa-market\"><span>Table of contents<\/span><\/a><\/p>\n<p style=\"text-align: justify;\"><span>1.&nbsp;&nbsp;&nbsp;Executive Summary: Hidradenitis Suppurativa (HS)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>2.&nbsp;&nbsp;&nbsp;SWOT Analysis: Hidradenitis Suppurativa (HS)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3.&nbsp;&nbsp;&nbsp;Hidradenitis Suppurativa (HS) Patient Share (%) Overview at a Glance<\/span><\/p>\n<p style=\"text-align: justify;\">3.1.&nbsp;&nbsp;&nbsp;&nbsp;Patient Share (%) Distribution of Hidradenitis Suppurativa in 2017 and 2030<\/p>\n<p style=\"text-align: justify;\"><span>4.&nbsp;&nbsp;&nbsp;Hidradenitis Suppurativa Market Overview at a Glance<\/span><\/p>\n<p style=\"text-align: justify;\">4.1.&nbsp;&nbsp;&nbsp;&nbsp;Market Share (%) Distribution of Hidradenitis Suppurativa in 2017<\/p>\n<p style=\"text-align: justify;\">4.2.&nbsp;&nbsp;&nbsp;&nbsp;Market Share (%) Distribution of Hidradenitis Suppurativa in 2030<\/p>\n<p style=\"text-align: justify;\"><span>5.&nbsp;&nbsp;&nbsp;Disease Overview: Hidradenitis Suppurativa (HS)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>5.1.&nbsp;Introduction<\/span><\/p>\n<p style=\"text-align: justify;\"><span>5.2.&nbsp;Causes and Symptoms of Hidradenitis Suppurativa (HS)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>5.3.&nbsp;Classification and Severity Assessment of Hidradenitis Suppurativa (HS)<\/span><\/p>\n<p style=\"text-align: justify;\">5.3.1.&nbsp;Hurley Stages of HS<\/p>\n<p style=\"text-align: justify;\">5.3.2.&nbsp;Modified Sartorius Score (MSS) of HS<\/p>\n<p style=\"text-align: justify;\">5.3.3.&nbsp;Physician Global Assessment of Hidradenitis Suppurativa (HS-PGA)<\/p>\n<p style=\"text-align: justify;\">5.3.4.&nbsp;Specific Severity Index of Hidradenitis Suppurativa (HSSI)<\/p>\n<p style=\"text-align: justify;\">5.3.5.&nbsp;Pathophysiology of Hidradenitis Suppurativa<\/p>\n<p style=\"text-align: justify;\">5.3.6.&nbsp;Genetic Basis of Hidradenitis Suppurativa (HS)<\/p>\n<p style=\"text-align: justify;\"><span>5.4.&nbsp;Diagnosis of Hidradenitis Suppurativa (HS)<\/span><\/p>\n<p style=\"text-align: justify;\">5.4.1.&nbsp;Differential Diagnoses<\/p>\n<p style=\"text-align: justify;\">5.4.2.&nbsp;Biomarkers of Hidradenitis Suppurativa (HS)<\/p>\n<p style=\"text-align: justify;\">5.4.3.&nbsp;Risk Factors and Complications<\/p>\n<p style=\"text-align: justify;\">5.4.4.&nbsp;Comorbidities<\/p>\n<p style=\"text-align: justify;\"><span>6.&nbsp;&nbsp;&nbsp;Epidemiology and Patient Population<\/span><\/p>\n<p style=\"text-align: justify;\">6.1.&nbsp;&nbsp;&nbsp;&nbsp;Key Findings<\/p>\n<p style=\"text-align: justify;\">6.2.&nbsp;&nbsp;&nbsp;&nbsp;Assumptions and Rationale: 7MM<\/p>\n<p style=\"text-align: justify;\">6.3.&nbsp;&nbsp;&nbsp;&nbsp;Total Prevalent Patient Population of HS in the 7MM<\/p>\n<p style=\"text-align: justify;\">6.4.&nbsp;&nbsp;&nbsp;&nbsp;Total Diagnosed Prevalent Patient Population of HS in the 7MM<\/p>\n<p style=\"text-align: justify;\">6.5.&nbsp;&nbsp;&nbsp;&nbsp;Gender-Specific Prevalent Patient Population of HS in the 7MM<\/p>\n<p style=\"text-align: justify;\">6.6.&nbsp;&nbsp;&nbsp;&nbsp;Age-Specific Prevalent Patient Population of HS in the 7MM<\/p>\n<p style=\"text-align: justify;\">6.7.&nbsp;&nbsp;&nbsp;&nbsp;Stage-Specific (Severity-specific) prevalent cases of HS in the 7MM<\/p>\n<p style=\"text-align: justify;\">6.8.&nbsp;&nbsp;&nbsp;&nbsp;Treated Prevalent Cases of HS in the 7MM<\/p>\n<p style=\"text-align: justify;\"><span>7.&nbsp;&nbsp;&nbsp;Country-wise Epidemiology of HS in the 7MM<\/span><\/p>\n<p style=\"text-align: justify;\"><span>7.1.&nbsp;United States<\/span><\/p>\n<p style=\"text-align: justify;\">7.1.1.&nbsp;Total Diagnosed Prevalent cases of HS in the United States<\/p>\n<p style=\"text-align: justify;\">7.1.2.&nbsp;Gender-Specific Prevalent cases of HS in the United States<\/p>\n<p style=\"text-align: justify;\">7.1.3.&nbsp;Age-Specific Prevalent cases of HS in the United States<\/p>\n<p style=\"text-align: justify;\">7.1.4.&nbsp;Stage-Specific Prevalent Cases of HS in the United States<\/p>\n<p style=\"text-align: justify;\">7.1.5.&nbsp;Treated Prevalent Cases of HS in the United States<\/p>\n<p style=\"text-align: justify;\"><span>7.2.&nbsp;EU5<\/span><\/p>\n<p style=\"text-align: justify;\"><span>7.2.1.&nbsp;&nbsp;&nbsp;Germany<\/span><\/p>\n<p style=\"text-align: justify;\">7.2.1.1.&nbsp;Total Diagnosed Prevalent cases of HS in Germany<\/p>\n<p style=\"text-align: justify;\">7.2.1.2.&nbsp;Gender-Specific Prevalent cases of HS in Germany<\/p>\n<p style=\"text-align: justify;\">7.2.1.3.&nbsp;Age-Specific Prevalent cases of HS in Germany<\/p>\n<p style=\"text-align: justify;\">7.2.1.4.&nbsp;Stage-Specific Prevalent Cases of HS in Germany<\/p>\n<p style=\"text-align: justify;\">7.2.1.5.&nbsp;Treated Prevalent Cases of HS in Germany<\/p>\n<p style=\"text-align: justify;\"><span>7.2.2.&nbsp;&nbsp;&nbsp;France<\/span><\/p>\n<p style=\"text-align: justify;\">7.2.2.1.&nbsp;Total Diagnosed Prevalent cases of HS in France<\/p>\n<p style=\"text-align: justify;\">7.2.2.2.&nbsp;Gender-Specific Prevalent cases of HS in France<\/p>\n<p style=\"text-align: justify;\">7.2.2.3.&nbsp;Age-Specific Prevalent cases of HS in France<\/p>\n<p style=\"text-align: justify;\">7.2.2.4.&nbsp;Stage-Specific Prevalent Cases of HS in France<\/p>\n<p style=\"text-align: justify;\">7.2.2.5.&nbsp;Treated Prevalent Cases of HS in France<\/p>\n<p style=\"text-align: justify;\"><span>7.2.3.&nbsp;&nbsp;&nbsp;Italy<\/span><\/p>\n<p style=\"text-align: justify;\">7.2.3.1.&nbsp;Total Diagnosed Prevalent cases of HS in Italy<\/p>\n<p style=\"text-align: justify;\">7.2.3.2.&nbsp;Gender-Specific Prevalent cases of HS in Italy<\/p>\n<p style=\"text-align: justify;\">7.2.3.3.&nbsp;Age-Specific Prevalent cases of HS in Italy<\/p>\n<p style=\"text-align: justify;\">7.2.3.4.&nbsp;Stage-Specific Prevalent Cases of HS in Italy<\/p>\n<p style=\"text-align: justify;\">7.2.3.5.&nbsp;Treated Prevalent Cases of HS in Italy<\/p>\n<p style=\"text-align: justify;\"><span>7.2.4.&nbsp;&nbsp;&nbsp;Spain<\/span><\/p>\n<p style=\"text-align: justify;\">7.2.4.1.&nbsp;Total Diagnosed Prevalent cases of HS in Spain<\/p>\n<p style=\"text-align: justify;\">7.2.4.2.&nbsp;Gender-Specific Prevalent cases of HS in Spain<\/p>\n<p style=\"text-align: justify;\">7.2.4.3.&nbsp;Age-Specific Prevalent cases of HS in Spain<\/p>\n<p style=\"text-align: justify;\">7.2.4.4.&nbsp;Stage-Specific Prevalent Cases of HS in Spain<\/p>\n<p style=\"text-align: justify;\">7.2.4.5.&nbsp;Treated Prevalent Cases of HS in Spain<\/p>\n<p style=\"text-align: justify;\"><span>7.2.5.&nbsp;&nbsp;&nbsp;United Kingdom<\/span><\/p>\n<p style=\"text-align: justify;\">7.2.5.1.&nbsp;Total Diagnosed Prevalent cases of HS in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">7.2.5.2.&nbsp;Gender-Specific Prevalent cases of HS in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">7.2.5.3.&nbsp;Age-Specific Prevalent cases of HS in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">7.2.5.4.&nbsp;Stage-Specific Prevalent Cases of HS in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">7.2.5.5.&nbsp;Treated Prevalent Cases of HS in the United Kingdom<\/p>\n<p style=\"text-align: justify;\"><span>7.3.&nbsp;Japan<\/span><\/p>\n<p style=\"text-align: justify;\">7.3.1.&nbsp;Total Diagnosed Prevalent cases of HS in Japan<\/p>\n<p style=\"text-align: justify;\">7.3.2.&nbsp;Gender-Specific Prevalent cases of HS in Japan<\/p>\n<p style=\"text-align: justify;\">7.3.3.&nbsp;Age-Specific Prevalent cases of HS in Japan<\/p>\n<p style=\"text-align: justify;\">7.3.4.&nbsp;Stage-Specific Prevalent Cases of HS in Japan<\/p>\n<p style=\"text-align: justify;\">7.3.5.&nbsp;Treated Prevalent Cases of HS in Japan<\/p>\n<p style=\"text-align: justify;\"><span>8.&nbsp;&nbsp;&nbsp;Current Treatment Practices<\/span><\/p>\n<p style=\"text-align: justify;\">8.1.&nbsp;&nbsp;&nbsp;&nbsp;European S1 Guideline for the Treatment of Hidradenitis Suppurativa\/Acne Inversa<\/p>\n<p style=\"text-align: justify;\">8.1.1.&nbsp;Medical therapy<\/p>\n<p style=\"text-align: justify;\">8.1.2.&nbsp;Surgical therapy<\/p>\n<p style=\"text-align: justify;\">8.2.&nbsp;&nbsp;&nbsp;&nbsp;North American Clinical Management Guidelines for HS<\/p>\n<p style=\"text-align: justify;\">8.3.&nbsp;&nbsp;&nbsp;&nbsp;British Association of Dermatologists guidelines for the management of Hidradenitis Suppurativa (Acne Inversa) 2018<\/p>\n<p style=\"text-align: justify;\">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span>Patient Journey of Hidradenitis Suppurativa (HS<\/span>)<\/p>\n<p style=\"text-align: justify;\"><span>10.&nbsp;Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>11.&nbsp;Key Endpoints in Hidradenitis Suppurativa (HS) Clinical Trials<\/span><\/p>\n<p style=\"text-align: justify;\"><span>12.&nbsp;Marketed Drugs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>12.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Humira: AbbVie<\/span><\/p>\n<p style=\"text-align: justify;\">12.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">12.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory milestones<\/p>\n<p style=\"text-align: justify;\">12.1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other developmental Activities<\/p>\n<p style=\"text-align: justify;\">12.1.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pivotal Clinical Trials<\/p>\n<p style=\"text-align: justify;\">12.1.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Summary of Pivotal Clinical Trials<\/p>\n<p style=\"text-align: justify;\"><span>13.&nbsp;Emerging Therapies<\/span><\/p>\n<p style=\"text-align: justify;\"><span>13.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Key Cross of Emerging Therapies<\/span><\/p>\n<p style=\"text-align: justify;\"><span>13.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IFX-1: InflaRx<\/span><\/p>\n<p style=\"text-align: justify;\">13.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.2.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Trials Information<\/p>\n<p style=\"text-align: justify;\">13.2.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\"><span>13.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cosentyx (Secukinumab): Novartis Pharmaceuticals<\/span><\/p>\n<p style=\"text-align: justify;\">13.3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.3.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.3.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Trials Information<\/p>\n<p style=\"text-align: justify;\">13.3.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\"><span>13.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;INCB054707: Incyte Corporation<\/span><\/p>\n<p style=\"text-align: justify;\">13.4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.4.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Trials Information<\/p>\n<p style=\"text-align: justify;\"><span>13.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CJM112: Novartis Pharmaceuticals<\/span><\/p>\n<p style=\"text-align: justify;\">13.5.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.5.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.5.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.5.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Trials Information<\/p>\n<p style=\"text-align: justify;\">13.5.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\"><span>13.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bimekizumab: UCB Biopharma S.P.R.L.<\/span><\/p>\n<p style=\"text-align: justify;\">13.6.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.6.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.6.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.6.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Trials Information<\/p>\n<p style=\"text-align: justify;\"><span>13.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bermekimab (MABp1): Janssen Pharmaceutical<\/span><\/p>\n<p style=\"text-align: justify;\">13.7.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.7.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.7.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.7.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Trials Information<\/p>\n<p style=\"text-align: justify;\">13.7.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\"><span>13.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CFZ533 (Iscalimab) and LYS006: Novartis<\/span><\/p>\n<p style=\"text-align: justify;\">13.8.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.8.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.8.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.8.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Trials Information<\/p>\n<p style=\"text-align: justify;\"><span>13.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Apremilast: Celgene<\/span><\/p>\n<p style=\"text-align: justify;\">13.9.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.9.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.9.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Trials Information<\/p>\n<p style=\"text-align: justify;\">13.9.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\"><span>13.10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Avacopan: ChemoCentryx<\/span><\/p>\n<p style=\"text-align: justify;\">13.10.1.&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.10.2.&nbsp;Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.10.3.&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.10.4.&nbsp;Clinical Trials Information<\/p>\n<p style=\"text-align: justify;\"><span>13.11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PF-06650833, PF-06700841, and PF-06826647: Pfizer<\/span><\/p>\n<p style=\"text-align: justify;\">13.11.1.&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.11.2.&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.11.3.&nbsp;Clinical Trials Information<\/p>\n<p style=\"text-align: justify;\"><span>13.12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Risankizumab: AbbVie<\/span><\/p>\n<p style=\"text-align: justify;\">13.12.1.&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.12.2.&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.12.3.&nbsp;Clinical Trials Information<\/p>\n<p style=\"text-align: justify;\"><span>13.13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Guselkumab: Janssen Pharmaceutical<\/span><\/p>\n<p style=\"text-align: justify;\">13.13.1.&nbsp;Product Description<\/p>\n<p style=\"text-align: justify;\">13.13.2.&nbsp;Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">13.13.3.&nbsp;Clinical Development<\/p>\n<p style=\"text-align: justify;\">13.13.4.&nbsp;Clinical Trials Information<\/p>\n<p style=\"text-align: justify;\"><span>14.&nbsp;Attribute Analysis of Hidradenitis Suppurativa (HS) Therapies<\/span><\/p>\n<p style=\"text-align: justify;\"><span>15.&nbsp;Hidradenitis Suppurativa (HS): 7 Major Market Analysis<\/span><\/p>\n<p style=\"text-align: justify;\">15.1. Key Findings<\/p>\n<p style=\"text-align: justify;\">15.2. Market Size of Hidradenitis Suppurativa in 7MM<\/p>\n<p style=\"text-align: justify;\">15.3. Market Size by therapies of Hidradenitis Suppurativa in 7MM<\/p>\n<p style=\"text-align: justify;\"><span>16.&nbsp;Market Outlook: 7MM<\/span><\/p>\n<p style=\"text-align: justify;\"><span>16.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;United States Market Size<\/span><\/p>\n<p style=\"text-align: justify;\">16.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Market size of Hidradenitis Suppurativa<\/p>\n<p style=\"text-align: justify;\">16.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hidradenitis Suppurativa Market by Therapies<\/p>\n<p style=\"text-align: justify;\"><span>17.&nbsp;EU-5 Countries<\/span><\/p>\n<p style=\"text-align: justify;\"><span>17.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Germany Market Size<\/span><\/p>\n<p style=\"text-align: justify;\">17.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Market size of Hidradenitis Suppurativa<\/p>\n<p style=\"text-align: justify;\">17.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hidradenitis Suppurativa Market by Therapies<\/p>\n<p style=\"text-align: justify;\"><span>17.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;France Market Size<\/span><\/p>\n<p style=\"text-align: justify;\">17.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Market size of Hidradenitis Suppurativa<\/p>\n<p style=\"text-align: justify;\">17.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hidradenitis Suppurativa Market by Therapies<\/p>\n<p style=\"text-align: justify;\"><span>17.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Italy Market Size<\/span><\/p>\n<p style=\"text-align: justify;\">17.3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Market size of Hidradenitis Suppurativa<\/p>\n<p style=\"text-align: justify;\">17.3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hidradenitis Suppurativa Market by Therapies<\/p>\n<p style=\"text-align: justify;\"><span>17.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Spain Market Size<\/span><\/p>\n<p style=\"text-align: justify;\">17.4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Market size of Hidradenitis Suppurativa<\/p>\n<p style=\"text-align: justify;\">17.4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hidradenitis Suppurativa Market by Therapies<\/p>\n<p style=\"text-align: justify;\"><span>17.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;United Kingdom Market Size<\/span><\/p>\n<p style=\"text-align: justify;\">17.5.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Market size of Hidradenitis Suppurativa<\/p>\n<p style=\"text-align: justify;\">17.5.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hidradenitis Suppurativa Market by Therapies<\/p>\n<p style=\"text-align: justify;\"><span>18.&nbsp;Japan<\/span><\/p>\n<p style=\"text-align: justify;\">18.1. Total Market size of Hidradenitis Suppurativa<\/p>\n<p style=\"text-align: justify;\">18.2. Hidradenitis Suppurativa Market by Therapies<\/p>\n<p style=\"text-align: justify;\"><span>19.&nbsp;Market Access and Reimbursement Scenario of Hidradenitis Suppurativa (HS) Therapies&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span>20.&nbsp;Market Drivers<\/span><\/p>\n<p style=\"text-align: justify;\"><span>21.&nbsp;Market Barriers<\/span><\/p>\n<p style=\"text-align: justify;\"><span>22.&nbsp;Appendix<\/span><\/p>\n<p style=\"text-align: justify;\">22.1. Bibliography<\/p>\n<p style=\"text-align: justify;\">22.2. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><span>23.&nbsp;Disclaimer<\/span><\/p>\n<p style=\"text-align: justify;\"><span>24.&nbsp;DelveInsight Capabilities<\/span><\/p>\n<p style=\"text-align: justify;\"><span>25.&nbsp;About DelveInsight<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hidradenitis-suppurativa-market-size-share-trends-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hidradenitis-suppurativa-market-size-share-trends-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018Hidradenitis Suppurativa Market Insights, Epidemiology and Market Forecast-2030\u2019 report delivers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hidradenitis-suppurativa-market-size-share-trends-epidemiology-forecast-till-2030_501299.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-501299","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=501299"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501299\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=501299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=501299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=501299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}